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Capsid dissociationThe mechanism by which host factors contribute to hepatitis B virus (HBV) capsid formation during the viral
life cycle remains unclear. This study analyzed the interaction between heat shock protein 90 (Hsp90), a host
factor, and the HBV core protein. Hsp90 was found to bind to HBV core protein dimers, which was then
encapsidated into the HBV capsid. Furthermore, activated Hsp90 may facilitate the formation of the human
HBV capsid by catalyzing core assembly and reducing the degree of capsid dissociation at various
temperatures, both in vitro and in vivo, and when subjected to detergent treatments in vitro. In addition,
inhibition or downregulation of Hsp90 reduced HBV production in HepG2.2.15 cells. These results showed
that Hsp90 plays an important role in HBV capsid stabilization and HBV formation.l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Human hepatitis B virus (HBV) is a member of the Hepadnaviridae
family and has infected over 2 billion people worldwide (Van-
landschoot et al., 2003). Chronic HBV infection is associated with liver
disease, including chronic hepatitis, liver cirrhosis, and hepatocellular
carcinoma (HCC), particularly in Asian and African cases (Zuckerman,
1999).
The HBV genome consists of a partially double-stranded 3.2-kb
circular DNA that encodes four proteins: a surface protein (HBs), a
core protein (HBc), a polymerase (HBV pol), and an X protein (HBx)
(Seeger and Mason, 2000). The core protein plays an essential role in
the HBV life cycle by packaging HBV pol, pre-genomic RNA (pgRNA),
and other components, such as heat shock proteins and protein
kinases (Seeger and Mason, 2000). Since the virus is generated by the
assembly of core proteins with the viral genome and other proteins,
core assembly is a critical step in HBV replication.
The core protein consists of 183–185 amino acids and is organized
into two domains: an N-terminal domain (amino acids 1–149;
Cp149), which is involved in core assembly, and a C-terminal domain
(amino acids 150–183 or 185), which regulates viral replication
(Seeger and Mason, 2000). Cp149, a 34-residue, C-terminal truncatedform, spontaneously forms a capsid under suitable conditions in vitro
and in vivo (Kim et al., 2001). This protein has been used to study
capsid assembly because it can be overexpressed in Escherichia coli
more efﬁciently than the full-length core protein and is structurally
similar to the HBV core protein (Biermer et al., 2003). Capsid
formation is a key event in the viral life cycle because the capsid
protects packaged viral and host factors. The identity of the host
factors, such as heat shock proteins, that interact with the core protein
and affect HBV capsid formation is unknown.
Heat shock protein 90 (Hsp90) is composed of three domains: an
N-terminal ATP-binding domain, a middle domain, and a C-terminal
dimerization domain (Prodromou et al., 1997; Stebbins et al., 1997;
Terasawa et al., 2005). Hsp90, which functions in an ATP-dependent
manner and often together with a co-chaperone, interacts with
various proteins, including kinases and transcription factors, and
controls biological processes by stabilizing protein folding (Cho et al.,
2000a,b; Clark et al., 2009; Ganem and Varmus, 1987; Hu et al., 2004,
2002). Geldanamycin (GA) binds directly to the ATP-binding domain
of Hsp90, thereby preventing ATP binding and reducing its afﬁnity for
client proteins (Buchner, 1999; Ujino et al., 2009).
Hsp90 is known to be involved in duck HBV replication. During
duck HBV replication, Hsp90 and the co-chaperone p23 bind together
and affect HBV pol activity. Moreover, Hsp90 becomes encapsidated
with the duck HBV pol/pgRNA complex (Clark et al., 2009; Hu et al.,
1997). Human and duck HBV replication are similar in that Hsp90
binds to HBV pol and affects HBV pol activity in both strains of the
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differs from duck HBV in that Hsp90 makes human HBV pol
competent for in vitro priming rather than simply maintaining the
human HBV pol/pgRNA complex (Gyoo Park et al., 2002).
HBV pol is known to bind to humanHBV core proteins before being
packaged into capsids (Lott et al., 2000), and also to Hsp90 and p23
(Hu et al., 1997). However, the relationship between Hsp90 and
human HBV core proteins is unknown.
In this study, we established that Hsp90 binds to core protein
dimers, but not to the capsid surface, and that Hsp90 is internalized
into the human HBV capsid when Hsp90-bound core protein dimers
form the capsid. This work demonstrates that Hsp90 can be packaged
into the capsid by interacting not only with the HBV pol/pgRNA
complex but also with core proteins. Furthermore, the presence of
activated Hsp90 and HBV core protein dimers not only facilitated
capsid formation but also reduced capsid dissociation when subjected
to various temperatures and detergent treatments.
Results
Hsp90 binds to HBV core protein dimers
To determine if Hsp90 binds to HBV core proteins, a co-immuno-
precipitation (co-IP) analysis was performed. The results show that
Hsp90 binds to the HBV core protein (Fig. 1A). The location of the
interaction between the Hsp90 and the HBV core protein was
investigated by co-IP and binding assays using puriﬁed proteins.
Hsp90 was found to bind to Cp149 dimers but not to the capsid surface
(Fig. 1B and C). In addition, each binding site was identiﬁed (Fig. S1).
Hsp90 is incorporated into the HBV capsid through binding
with Cp149 dimers
In ducks, Hsp90 is packaged into the capsid by interacting with the
duck HBV pol/pgRNA complex (Hu et al., 1997; Nassal, 1999). WeFig. 1.Hsp90 binds to the HBV core protein. (A) The human hepatoma cell line, Huh7, was tra
cells were co-immunoprecipitated using anti-HBV core Ab and anti-Hsp90 Ab. Immunoblot
total protein mixture was used as the positive control. Non-speciﬁc IgG was used as the nega
reaction buffer. Themixture was co-immunoprecipitated using anti-HBV core Ab and anti-Hs
HBV core Ab and anti-Hsp90 Ab (top panel). Capsid was formed in an assembly reaction w
(bottom panel). An input of 5% of the total protein mixture was used as the positive co
immobilized on Ni-NTA agarose, and Cp149 dimers (top panel) and capsid (bottom panel) w
lane 3, Ni-NTA agarose alone; lane 4, Hsp90 immobilized on agarose (3%); lane 5, ﬂow-throug
lane 9, 500 mM imidazole elution.sought to determine whether an alternative pathway of Hsp90
packaging into human HBV capsid exists other than the pathway
described for duck HBV. Since Hsp90 binds to Cp149 dimers, we
assumed that this may be themechanism bywhich Hsp90 is packaged
into the capsid. Sucrose density gradient analysis showed that when
Hsp90 was mixed with Cp149 dimers, Hsp90 was present in fractions
8–10. The capsid was also detected in these fractions after the
assembly reaction (Fig. 2A). When Hsp90 was mixed with BSA
(control), it was detected in fractions 2–4 (data not shown). Two
samples each from fractions 3 and 8 (Fig. 2A) were examined under
non-denaturing and denaturing conditions to conﬁrm Hsp90 pack-
aging into the capsid. SDS-PAGE revealed the presence of Hsp90 in
fractions 3 and 8 (Fig. 2B, lanes 3 and 4, bottom panel). However, dot
blot and native agarose gel analyses, which do not interfere with
capsid formation, showed no detectable Hsp90 in the fraction 3 and
8 samples (Fig. 2B, top and middle panels). Hsp90 may be
undetectable in the fraction 8 sample due to its localization inside
the capsid. Since native agarose gel electrophoresis can only detect
the capsid, Cp149 was only detectable in the fraction 8 sample
(Fig. 2B, lane 4 of middle panel). In addition, dot blot analysis detected
Hsp90 and Cp149 dimers (Fig. S2). From these results, we conclude an
alternative packaging pathway where Hsp90 is packaged into the
capsid by binding to Cp149 dimers.
Activated Hsp90 facilitates HBV core protein assembly
HBV core assembly begins with Cp149 homodimer formation
through a cysteine disulﬁde bond between the 61st amino acid of each
subunit (Nassal et al., 1992; Zheng et al., 1992). Hsp90 activity
requires protein p23 binding and ATP, and its activity facilitates
maturation of the client protein (Sullivan et al., 1997; Woo et al.,
2009). To examine whether activated Hsp90 affects HBV core
assembly, an assembly reaction with Cp149 dimers or a core protein
point mutant (C61A) in the presence of Hsp90 was performed. The
presence of activated Hsp90 facilitated capsid formation (Fig. 3A) notnsfected with pCMV/Flag-core to express the HBV core protein. Lysates from transfected
analysis was performed with anti-Flag M2 Ab and anti-Hsp90 Ab. An input of 4% of the
tive control. (B) Cp149 dimers were mixed with Hsp90 and incubated at 30 °C for 1 h in
p90 Ab and analyzed by 15% SDS-PAGE. Immunoblot analysis was performed using anti-
ith 20 μM Cp149 dimers and Hsp90. Co-immunoprecipitation was performed as above
ntrol. Non-speciﬁc IgG was used as the negative control. (C) His-tagged Hsp90 was
ere independently loaded on the agarose. Lane 1, puriﬁed Cp149; lane 2, puriﬁed Hsp90;
h; lanes 6–8, 50 mM imidazole washes to show protein that did not bind to agarose; and
Fig. 2. Hsp90 is incorporated into the HBV capsid by interaction with Cp149 dimers.
(A) To perform the assembly reaction, Hsp90 was mixed with Cp149 dimers and
assembly was tracked by sucrose density gradient analysis. Cp149 and Hsp90 were
analyzed by immunoblot analysis using anti-HBV core Ab and anti-Hsp90 Ab,
respectively. The positive control was 5% of the total loading volume. (B) Non-
denaturing conditions were applied to samples from fractions 3 and 8 of (A), and the
reactions were analyzed by dot blot analysis (top panel) and native agarose gel
electrophoresis on a 0.9% agarose gel (middle panel). The two samples were analyzed
by 15% SDS-PAGE under denaturing conditions (bottom panel). Then, each sample,
under various conditions, was probed with the anti-HBV core Ab and anti-Hsp90 Ab.
Both Cp149 (lane 1) and Hsp90 (lane 2) were puriﬁed from E. coli and used as markers.
Samples from fractions 3 and 8 of (A) (lanes 3 and 4 of (B), respectively) were included
in the analysis.
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did not form in the absence of Hsp90 or in the presence of Hsp90
inactivated by GA treatment (Fig. 3B). In addition, sucrose density
gradient analysis showed that capsid formation increased in the
presence of ATP-activated Hsp90 but was unaffected by BSA or Hsp90
inactivated by GA (Fig. 3C). To conﬁrm that activated Hsp90 facilitates
HBV core assembly, activated Hsp90, an Hsp90 mutant (N190Δ, in
which the ATPase site was deleted), and a BSA (control) were
independently added to Cp149 dimers and capsid formation was
assessed in a time-course experiment. Capsid formation in the
presence of activated Hsp90 was faster than in the presence of the
Hsp90 mutant or BSA. The Hsp90 deletion mutant (N190Δ) slowed
the saturation of capsid formation to 120 min, as did the absence of
Hsp90 (i.e., the BSA control) (Fig. 3D). The intensity of the Cp149
dimer band at 15 min after the assembly reaction was set to 1, and the
relative intensities of the other bands were analyzed in comparison to
this band. Identical amounts of Cp149 were added to each group.
Thus, capsid levels in all samples were saturated at 120 min (Fig. 3D,
right graph).
HBV capsid formation facilitated by activated Hsp90 is regulated by
temperature changes
The above results clearly demonstrate that activated Hsp90
facilitates capsid formation (Fig. 3). Hsp90 activity is known to
suppress thermal stress-protein aggregation and protect unfolded
proteins from fully unfolding while promoting rapid recovery
(Freeman and Morimoto, 1996; Yonehara et al., 1996). The HBV
capsid formation from HBV core protein dimers is temperature-
dependent (Hilmer et al., 2008). To determine how activated Hsp90
affects HBV capsid formation at varying temperature, capsid forma-
tion in vitrowas assessed over a range of temperatures in the presence
of (1) Cp149 dimers and BSA (control), (2) Cp149 dimers andactivated Hsp90, and (3) Cp149 dimers and GA-treated Hsp90. In the
control experiment, capsid formation peaked at 37 °C (Fig. 4A, left
panel). In Cp149 dimer and activated Hsp90 experiment, capsid
formation peaked over a wide range of temperatures, from 30 °C to
43 °C, and at levels that were twice the control levels (Fig. 4A, middle
panel). To demonstrate that capsid assembly was stabilized exclu-
sively by activated Hsp90, GA was added to Hsp90 and Cp149 dimers.
GA treatment reversed the effect of Hsp90 and resulted in the same
pattern as when using Cp149 and BSA (Fig. 4A, right panel). To assess
the effect of Hsp90 on HBV capsid formation in cells at various
temperatures, pCMV/Flag-core was transfected into Huh7 cells, and
the cells were treated with GA. After heat shock, HBV capsid levels
were measured by immunoblot analysis. In contrast to results
obtained using puriﬁed proteins (Fig. 4A, middle panel), capsid
formation levels in cells not treated with GA remained constant,
regardless of the temperature (Fig. 4B, left panel). This is because
capsid formation saturated during the 48 h incubation after transfec-
tion. Heat shock after treatment with GA, however, affected capsid
formation; the levels decreased relative to capsid formation levels in
cells not treated with GA at all temperatures except 37 °C (Fig. 4B,
right panel). A similar result was obtained for the experiment
conducted only in the presence of Hsp90 (data not shown). Hsp90
inactivated by GA cannot facilitate temperature-dependent capsid
formation, reﬂecting the same pattern as the experiment using
puriﬁed proteins. These results support the hypothesis that activated
Hsp90 stabilizes capsid formation under temperatures ranging from
30 to 43 °C.
Activated Hsp90 decreases detergent-mediated dissociation of the
HBV capsid
Next, we assessed the protective effect of Hsp90 on capsid
dissociation in the presence of denaturing agents. Capsids were
treated with varying detergent concentrations, including urea and
SDS, at 37 °C for 30 min. When capsids were treated with 3 M urea,
activated Hsp90 (Fig. 5A, middle panel) maintained capsid levels 2.7-
fold higher than in the absence of Hsp90 (Fig. 5A, left panel) or in the
presence of Hsp90 treated with GA (Fig. 5A, right panel). Capsid levels
after 0.05% SDS treatment were 2.4-fold higher in the presence of
activated Hsp90 (Fig. 5B, middle panel) than in the absence of Hsp90
(Fig. 5B, left panel) or in the presence of Hsp90 treated with GA
(Fig. 5B, right panel). The shielding effect of Hsp90 on capsid
dissociation disappeared as SDS concentration exceeded 0.1%, and
all capsids dissociated beyond this point (Fig. 5B). To monitor HBV
capsid dissociation in response to detergent treatment, Cp149 dimers
assembled in vitro and treated with detergents were observed by
transmission electron microscopy. In a previous report, the diameter
of Cp149 was determined to be approximately 30 nm (Newman et al.,
2003). TEM data showed that, in the presence of activated Hsp90 and
in the untreated control, compact spherical capsids were formed with
an average diameter of 30 nm (Fig. 5C, D and F; average diameters,
30.5, 30.75, and 30.87 nm). However, in the presence of GA-
inactivated Hsp90, 95% of capsids formed were irregular complexes
or “shrinking capsids” (Fig. 5E) and 42% were “inﬂating capsids”
(Fig. 5G). These results show that activated Hsp90 reduces the HBV
capsid dissociation degree induced by detergents.
Both inhibition and downregulation of Hsp90 reduce the amount of
extracellular HBV DNA
HepG2.2.15 cells derived from HepG2 cells produce HBV (Liu et al.,
2009). To measure the amount of extracellular HBV DNA following
Hsp90 inhibition and downregulation, HepG2.2.15 cells were treated
with GA and transfected with shRNA-Hsp90. After 24 h, HBV DNA
isolated from the culture medium was quantiﬁed using real-time PCR
(qRT-PCR). Compared with untreated HepG2.2.15 cells, the amount of
Fig. 3. Hsp90 facilitates HBV core assembly. (A) Cp149 dimers and (B) the core protein point mutant (C61A) were independently combined with Hsp90, p23, 0.5 mM ATP-γ-S, and
2 μMGA, and subjected to the assembly reaction. Samples were analyzed by 0.9% agarose gel electrophoresis and evaluated by immunoblot analysis using anti-HBV core Ab to detect
the HBV capsid. Core, the total amount of Cp149 dimers, and C61A were analyzed by 15% SDS-PAGE. (C) Cp149 dimers and ATP-activated Hsp90 were mixed and incubated under
conditions permitting capsid assembly. Sucrose density gradient analysis was conducted (middle panel). Furthermore, Cp149 dimers were allowed to react with GA-inactivated
Hsp90 (bottom panel). BSA was used as a control (top panel). Each sample was assayed by immunoblot analysis using an anti-HBV core Ab with 5% of the total loading volume used
as the positive control. The bottom left graph shows the band pattern of the fractions on the top panel in comparison with the control. The bottom right graph compares the amount
of capsid formation in the presence of BSA, ATP-activated Hsp90, and Hsp90 inactivated by GA (fractions 7–10). The core intensity resulting from sucrose density gradient analysis of
Cp149 dimers with BSA was used as a standard. (D) Capsid formation was detected in an in vitro time-course experiment (0–120 min) by immunoblot analysis. Top panel, Cp149
dimers were incubatedwithout Hsp90, using BSA as a control. Middle panel, Cp149 dimers were incubated in the presence of ATP-activated Hsp90. Bottom panel, Cp149 dimers were
incubated with the ATPase site-deleted Hsp90 mutant (N190Δ). The right graph shows the band intensity pattern. Capsid intensity resulting from incubation of Cp149 dimers with
BSA for 15 min was used as a standard and assigned a value of 1. Each experiment was carried out three times, and the error bars represent standard deviation from the three
experiments.
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was reduced by 53% and 49%, respectively (Fig. 6A, lanes 3 and 4);
extracellular HBV DNA was also reduced (Fig. 6B, lanes 3 and 4, 50%
and 48%, respectively). Next, HepG2.2.15 cells were treated with
lamivudine (3TC) to inhibit HBV pol activity for 24 h. Extracellular
HBV DNA was reduced by 83% (Fig. 6B, lane 5), but there was no
change in capsid assembly (Fig. 6A, lane 5). Consistent with previous
studies’ results (Bouchard et al., 2003; Severini et al., 1995), this result
indicates that inhibition of polymerase activity by 3TC decreases
extracellular HBVDNA levels through inhibition of HBVDNA synthesis
in the cytoplasm; however, it does not decrease capsid assembly.
Importantly, HBV pol inhibition does not affect intracellular capsid
formation. Furthermore, when HepG2.2.15 cells were treated with
3TC and GA at the same time, the amounts of intracellular capsid and
extracellular HBV DNA were reduced by 62% and 63%, respectively,
compared to cells treated with 3TC only (Fig. 6B, lane 6). This means
that, on the premise that polymerase activity is inhibited by 3TC, the
reduced intracellular capsid levels due to Hsp90 inhibition affect the
amount of extracellular HBV DNA. Hsp90 levels, except for the shRNA-Hsp90 transfected sample, were constant in all samples. B-actin was
used as a control (Fig. 6C). These results suggest that Hsp90 is a host
factor that contributes to the amount of extracellular HBV DNA not
only through HBV pol activity but also through capsid assembly.Discussion
HBV capsid assembly is crucial to HBV replication in the HBV life
cycle. Host factors, such as heat shock proteins and protein kinases,
which are packaged into the HBV capsid with the HBV pol/pgRNA
complex, contribute to HBV replication in ducks and humans
(Bartenschlager and Schaller, 1992; Hirsch et al., 1990; Hu et al.,
2004, 1997; Kann and Gerlich, 1994; Nassal, 1999). Hsp90,one of the
host factors, affects polymerase priming and HBV pol/pgRNA complex
formation by interacting with the HBV pol (Cho et al., 2000a,b; Gyoo
Park et al., 2002; Hu et al., 2004, 2002; Wang et al., 2002).
Nonetheless, the relationship between Hsp90 and the HBV core
protein has never been studied.
Fig. 4.Hsp90 promotes HBV core assembly over a wide range of temperatures. (A) Cp149 dimers were incubated with BSA (control protein; left panel) at 30 °C for 30 min and then at
varying temperatures for 30 min. ATP-γ-S (0.5 mM)was added to Hsp90 at 30 °C for 30 min (middle panel) and GA (2 μM)was added to Hsp90 at 30 °C for 30 min (right panel), and
each mixture was incubated with Cp149 dimers at varying temperatures for 30 min. The amount of capsid formation was measured by immunoblot analysis using anti-HBV core
antibody at each temperature. Core, the total amount of Cp149 analyzed on 15% SDS-PAGE. C, total capsid formed by incubating Cp149 dimers alone at 30 °C for 30 min. Bottom
graph, intensity of the bands in the gel above, using the intensity of C as a standard (set to 1). These experiments were repeated three times and the error bars represent the standard
deviation from the three experiments. (B) Huh7 cells were transfected with pCMV/Flag-core. Cells were incubated at 30, 35, 37, 40, and 43 °C for 2 h with no treatment (left panel) or
4 μM GA treatment (right panel). Capsids were analyzed by 0.9% agarose gel electrophoresis and detected by immunoblot analysis with anti-FLAG M2 Ab. Hsp90, β-actin, and HBV
core protein expression were assessed by immunoblot analysis on 15% SDS-PAGE. Bottom graph, band intensity of the sample incubated at 37 °C of (B) (left panel) was used as a
standard (set to 1), and the intensity of the other bands was compared to this value. These experiments were repeated three times, and the error bars represent the standard
deviation of the three experiments.
165H.Y. Shim et al. / Virology 410 (2011) 161–169Both Hsp90 and another host factor, DD3X DEAD-box RNA
helicase, which unwinds RNA in an ATPase-dependent manner, are
encapsidated by binding the HBV pol (Hu et al., 2004, 2002; Wang et
al., 2009). However, we discovered a relationship between Hsp90 and
the HBV core protein and determined that Hsp90 interacts with HBV
core protein dimers to be packaged into the capsid (Figs. 1 and 2).
These results differ from current hypotheses on the encapsidation
pathway of Hsp90. Most importantly, our study presents a new
mechanism by which Hsp90 is packaged into the HBV capsid. In
further experiments, we identiﬁed that Hsp90, HBV core protein, and
HBV pol form a complex, although HBV pol and core protein were
identiﬁed by only a two-peptide sequence using MS/MS analysis
(Thermo Fisher Scientiﬁc, Inc.) (Table S1). Combined with the results
of previous studies that showed HBV pol binding to Hsp90 (Cho et al.,
2000a,b) and HBV core protein (Lott et al., 2000), our results indicate
Hsp90, HBV core dimer, andHBV polmay form a complex. Therefore, a
more extensive study on the relationship among Hsp90, HBV coreprotein, and HBV pol is required to fully understand the process of
HBV replication.
The effect of molecular chaperones on capsid formation during
HBV replication is not clear. However, protein kinase A (PKA) and
protein kinase C (PKC) activities increase HBV core assembly and
capsid stability (Kang et al., 2008, 2006), but a host factor, Hsp40,
decreases HBV replication and capsid formation by binding to the HBV
core protein (Sohn et al., 2006). Additionally, Hsp90 binds P1, the core
protein of picornaviruses, along with p23 (Geller et al., 2007), but the
effect of Hsp90 is different. In contrast to our ﬁnding that Hsp90
facilitates HBV core assembly by binding to the HBV core protein
(Fig. 3), Hsp90 binds P1 to prevent capsid degradation caused by the
viral-encoded protease in picornaviruses (Geller et al., 2007).
HBV Cp149 is an arginine-rich domain (ARD), a truncated form of
full-length core protein (Newman et al., 2009). In addition, HBV
Cp149 assembles spontaneously to form the capsid under optimal
conditions (Wingﬁeld et al., 1995), but it can dissociate in some
Fig. 5. Hsp90 inhibits HBV capsid dissociation under detergent treatment. (A) Cp149 dimers were incubated at 37 °C for 30 min. After capsid formation, varying urea concentrations
(0–3 M) were added and the capsids were incubated with BSA, ATP-activated Hsp90, or GA-treated Hsp90 at 37 °C for 30 min. Mixtures were analyzed by 0.9% agarose gel
electrophoresis, and proteins were detected by immunoblot analysis using anti-HBV core Ab (top panel) and Coomassie blue (bottom panel). (B) Capsids were treated with different
concentrations of SDS (0–0.5%) in the presence of BSA, ATP-activated Hsp90, or GA-treated Hsp90 at 37 °C for 30 min. Mixtures were then immediately analyzed by 0.9% agarose gel
electrophoresis as described above. Coomassie staining was used tomeasure the amount of capsid and denatured capsid. Core, the total amount of Cp149 analyzed on 15% SDS-PAGE.
C, the amount of capsid not treated with detergents. Bottom graph, C was used as the standard (set to 1), and the intensity of the other bands was compared to this value. These
experiments were repeated three times, and the error bars represent standard deviation of the three experiments. Capsids were examined by electron microscopy in the presence of
detergent. (C) Capsids not exposed to detergents (urea or SDS) were used as the control. (D) Capsids and ATP-activated Hsp90 or GA-inactivated Hsp90 in the presence of 3 M urea.
(E) Capsids and ATP-activated Hsp90 or GA-inactivated Hsp90 in the presence of 0.05% SDS. The arrows indicate the detergent-dissociated capsid (urea or SDS).
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Fig. 6. Both inhibition and downregulation of Hsp90 reduce the amount of extracellular
HBV DNA in HepG2.2.15. (A) After HepG2.2.15 cells were treated with GA or 3TC and
transfected with shRNA-Hsp90 for 24 h, cells were lysed in lysis buffer and analyzed by
0.9% native agarose gel electrophoresis to detect HBV capsid (top panel) as well as 15%
SDS-PAGE to detect HBV core protein (bottom panel). (B) HBV capsid bands were
analyzed by ImageMaster 2D Elite software 4.01 (black bars) and HBV DNA in themedia
from cell cultures was measured by qRT-PCR (ABI 7300, Applied Biosystems) (grey
bars). (C) Cell lysates were analyzed by 15% SDS-PAGE to detect Hsp90. B-actin was
used as a control. Immunoblot analysis was performed using the anti-HBV core and
anti-Hsp90 Abs. These experiments were repeated three times, and the error bars
represent standard deviation of the three experiments. NC shRNA, the negative control
of shRNA (pLK0.1-scramble vector).
167H.Y. Shim et al. / Virology 410 (2011) 161–169external environments (Newman et al., 2003). Because activated
Hsp90 suppresses HBV capsid dissociation in detergents (Fig. 5), we
conclude that Hsp90 not only facilitates HBV capsid formation but also
decreases HBV capsid dissociation.
On the basis of these results, we hypothesize that Hsp90 increases
the afﬁnity between core protein dimers to induce HBV capsid
formation and maintains the core–core interaction to suppress HBV
capsid dissociation by binding the HBV core protein.
Inhibition of Hsp90 affects the ability of various viruses to
replicate. Inhibition of Hsp90 downregulates RNA replication in the
ﬂock house virus (Kampmueller and Miller, 2005) and suppresses
replication of the hepatitis C virus by blocking the function of
nonstructural protein 5A (NS5A), a viral replicase, and Hsp90 complex
(Okamoto et al., 2006). Our results show that both inhibition and
downregulation of Hsp90 decrease HBV titers and capsid levels
(Fig. 6). These results indicate that Hsp90 contributes to the
production of HBV particles through both polymerase activity and
capsid assembly.
Expression levels of Hsp90 increase in tumorous tissues (Lim et al.,
2002), and up-regulation of Hsp90 facilitates tumor cell invasion
induced by HBx to affect HBV-related tumor progression (Li et al.,
2010). Moreover, inhibition of Hsp90 induces the inactivation and
degradation of hepatocarcinogenesis-driving factors, suggesting that
Hsp90may play an important role in the development of HCC (Breinig
et al., 2009).
In conclusion, our study reveals that Hsp90 encapsidates into the
HBV capsid and increases HBV capsid stability by interacting with HBV
core protein dimers and that Hsp90 is related to the production of
HBV particles in HepG2.2.15 cells. These results provide new insights
into the mechanism of viral assembly and HBV replication, which areassociated with host factors. Furthermore, Hsp90 may be a new drug
development target for the treatment of HCC.
Materials and methods
Cell culture and transfection
Human hepatoma cell lines, Huh7 and HepG2.2.15, were cultured
in Dulbecco's modiﬁed Eagle's medium (DMEM) (Welgene, Daegu,
Republic of Korea) and 10% fetal bovine serum (FBS) (Invitrogen,
Carlsbad, CA, USA) and maintained at 37 °C in 5% CO2. The cells were
transfected with Fugene 6 (Roche, Mannheim, Germany) transfection
reagent as instructed by the manufacturer.
Expression and puriﬁcation of Cp149, Cp149 point mutants,
and p23 protein
Cp149 was cloned directly using a pET30a vector (Novagen,
Madison, WI, USA). Constructs were transformed into BL21(DE3)
+pLysS E. coli (Novagen, Madison,WI, USA) and puriﬁed as described
in a previous study (Choi et al., 2005). The core protein point mutant,
C61A, was constructed using a site-directed mutagenesis protocol
(Qiagen GmbH, Hilden, Germany). The following forward (F) and
reverse (R) primers were used, and pCMV/Flag-core (Kang et al.,
2008) was used as a template: C61A, F-5′-CAGGCAAGC-
TATTCTGGCTTGGGGTGAGTTGATG-3′ and R-5′- CATCAACTCACCC-
CAAGCCAGAATAGCTTGCCTG-3′. Puriﬁed core protein dimers were
stored in 100 mM glycine (pH 9.5). At this pH, core protein dimers are
stable (Wingﬁeld et al., 1995). For Cp149 assembly, the reaction buffer
(50 mMHepes (pH 7.5), 5 mMMgCl2, 15 mMNaCl, and 10 mM CaCl2)
was mixed with Cp149 and incubated at 37 °C for 30 min (Choi et al.,
2005). The p23 protein was directly cloned from a pET28b vector
(Novagen). Constructs were transformed into BL21(DE3)+pLysS E.
coli (Novagen) and puriﬁed as described in a previous study (Choi et
al., 2005).
Expression and puriﬁcation of Hsp90 and Hsp90 deletion mutant
Human Hsp90β was cloned into the expression vector pET28b
(Cho et al., 2000a). The Hsp90 mutant was ampliﬁed by PCR using
forward (F) and reverse (R) primers with pET28b-Hsp90β as the
template: N190Δ (191–724), F-5′-GCGGTCGACCAGAGTACCTAGAA-
GAGAGG-3′ and R-5′-CCGCGGCCGCCTAATCGACTTCTTCC-3′. This con-
struct has a hexa-histidine tag added to the N-terminus of Hsp90 (Cho
et al., 2000b) and the Hsp90 deletion mutant, which were over-
expressed in E. coli BL21(DE3) cells cultured in 2×YTmedium. Protein
expression was induced by 1 mM isopropyl-β-D-thiogalactopyrano-
side (IPTG), and the cells were incubated for an additional 20 h at
22 °C. The cells were lysed by sonication in lysis buffer (20 mM Tris–
HCl (pH 7.5), 500 mM NaCl, 5% (v/v) glycerol). The crude lysate was
centrifuged at 18,000 × g for 60 min. The supernatant was applied to
an afﬁnity chromatography column of nickel-nitrilotriacetic acid (Ni-
NTA)-agarose (Qiagen). The protein was eluted with lysis buffer
containing 500 mM imidazole.
Co-immunoprecipitation of the HBV core protein and Hsp90
For co-immunoprecipitation (co-IP) of Hsp90 with the HBV core
protein, Huh7 cells were transfected with pCMV/Flag-core. After 48 h,
cell lysates were co-immunoprecipitated with a mouse monoclonal
anti-HBV core antibody (Ab) (Santa Cruz, sc-23945) and a goat
polyclonal anti-Hsp90 Ab (Santa Cruz, sc-1057) at 4 °C for 2 h.
Immunoprecipitated lysates were analyzed by 15% SDS-PAGE fol-
lowed by immunoblot analysis with a mouse monoclonal anti-FLAG
M2 Ab (1:5000; Sigma, St. Louis, MO, F3165) and a goat polyclonal
anti-Hsp90 Ab (1:1000; Santa Cruz, sc-1057). For co-IP of Hsp90 with
168 H.Y. Shim et al. / Virology 410 (2011) 161–169Cp149 dimers or capsid, 20 μM of Cp149 dimers or capsid was added
to 20 μM of Hsp90 and the samples were incubated at 30 °C for 1 h.
Cp149 dimers (or capsid) and Hsp90 were co-immunoprecipitated as
described above. Immunoblot analysis was performed using a rabbit
polyclonal anti-HBV core Ab (1:4000; Dako, B0586) and a goat
polyclonal anti-Hsp90 Ab, 1:1000 (Santa Cruz, sc-1057).Binding assay of Hsp90 with the HBV core protein
To assay the binding of Hsp90 with the HBV Cp149 dimers and
capsid, 5 μg of His-tagged Hsp90 was bound to 100 μl of Ni-NTA
agarose at 4 °C for 1 h. The Hsp90-Ni-NTA mixture was loaded onto a
columnwith the bottom outlet capped. The bottom cap was removed,
and the column was drained. Next, 5 μg of each Cp149 dimers and
capsid were added to the column. Ni-NTA agarose-coupled proteins
were washed with TN buffer (20 mM Tris–HCl (pH 7.5), 100 mM
NaCl) 4 times and eluted with TN buffer containing 500 mM
imidazole. Eluates were analyzed on a 15% SDS-PAGE followed by
immunoblot analysis with a goat polyclonal anti-Hsp90 Ab (1:1000;
Santa Cruz, sc-1057) and a rabbit polyclonal anti-HBV core Ab
(1:4000; Dako, B0586).Sucrose density gradient analysis and dot blot assay
The assembly reaction was performed at 37 °C for 30 min in
reaction buffer. After the assembly reaction, sucrose density gradient
analysis was performed by ultra-centrifugation at 20 °C for 4 h 30 min
and 160,000 × g using a P55ST2 rotor of CP-100α (Hitachi Koki Co.
Ltd., Tokyo, Japan), and included gradient ranges of 10–50% (w/v)
sucrose in 50 mM Hepes (pH 7.5). Fractions were collected, loaded
onto a 15% SDS-PAGE, and subjected to immunoblot analysis with
rabbit polyclonal anti-HBV core Ab (1:4000; Dako, B0586) and goat
polyclonal anti-Hsp90 Ab (1:1000; Santa Cruz, sc-1057). Dot blot
analysis was performed according to the instructions in the Bio-Dot
Microﬁltration Apparatus manual (Bio-Rad Laboratories Inc., Hercu-
les, California, USA).Detection of the HBV capsid by native agarose gel electrophoresis
To study the effect of Hsp90 on HBV capsid formation, 20 μM
Cp149 dimer and 20 μM Hsp90 were incubated in reaction buffer
containing 20 mM Na2MoO4, 1 mM DTT, 0.01% NP-40, and 0.5 mM
adenosine 5′-O-(3-thiotriphosphate) (ATP-γ-S) (Sullivan et al., 1997).
Samples were incubated at 37 °C for 30 min, separated by electro-
phoresis on a 0.9% native agarose gel, and subjected to immunoblot
analysis with rabbit polyclonal anti-HBV core Ab (1:4000; Dako,
B0586) as described in a previous study (Kang et al., 2006). Capsid
bands were analyzed by ImageMaster 2D Elite software 4.01
(Amersham Pharmacia Biotechnology).Treatment with Hsp90 inhibitor and temperature changes in Huh7 cells
An Hsp90 inhibitor, geldanamycin (GA; 4 μM, A.G. Scientiﬁc, Inc.,
San Diego, CA, USA), was added to Huh7 cells. Cells were transfected
with pCMV/Flag-core to express the core protein. Cells were
transferred to a CO2 incubator at 30, 35, 37, 40, and 43 °C for 2 h.
After heat shock, cells were lysed in lysis buffer (50 mM Tris–HCl (pH
8.0), 150 mM NaCl, 5 mM EDTA, and 0.5% NP-40) and centrifuged at
16,000 ×g for 15 min to remove debris. Cleared lysates were
separated by electrophoresis on a 0.9% native agarose gel, followed
by immunoblot analysis with a mouse monoclonal anti-FLAG M2 Ab
(1:5000; Sigma, F3165).Detection of HBV capsid stability following urea and SDS treatment
Assembled Cp149 and Hsp90 were incubated at the indicated
concentrations of urea (0–3 M) or SDS (0–1%). Samples were
incubated at 37 °C for 30 min, separated by electrophoresis on a
0.9% native agarose gel, and subjected to immunoblot analysis with a
rabbit polyclonal anti-HBV core Ab (1:4000; Dako, B0586).
Transmission electron microscopy for HBV capsid dissociation following
urea and SDS treatment
In vitro assembly of Cp149 was performed and treated with urea
and SDS. For negative staining, 10 μl of a solution containing assembled
Cp149was applied to a carbon-coated grid, and the gridwas incubated
for 1 min. The grid was stained with 2% uranyl acetate for 1 min and
washedwithwater. Transmission electronmicrographswere taken on
a JEM 1010 (JEOL, Tokyo, Japan) operating at 80 kV at the NICEM
(National Instrumentation Center for Environmental Management).
Quantiﬁcation of HBV DNA by real-time quantitative PCR
HepG2.2.15 cells were treated with 4 μM GA or 85 μM lamivudine
(3TC) (HBV pol inhibitor) (Allen et al., 1998; Doong et al., 1991;
Severini et al., 1995), and transfected with shRNA-Hsp90 (Sigma,
MISSION shRNA NM_007355) and negative control plasmid pLK0.1.
After 24 h, the medium was collected and the released HBV virus was
harvested. After extraction with phenol, the DNA was precipitated in
ethanol. The DNA was added to a real-time PCR SYBR-Green reaction
mixture (Qiagen, Hilden, Germany) containing HotStarTaq polymer-
ase, which was included to avoid false positives in the quantitative
PCR. The primers, F-5′-GTGTCTGCGGCGTTTTATCA-3′ and R-5′-
GACAAACGGGCAACATACCTT-3′, were designed to amplify a 98-base
pair product from positions 379 to 476 of the HBV genome (Garson et
al., 2005). The reaction conditions were 95 °C for 15 min, followed by
40 cycles at 94 °C for 15 s, 55 °C for 30 s and 72 °C for 30 s. The level of
HBV in the medium was quantiﬁed relative to a standard curve of
serial dilutions (5.28×106 copies per milliliter (cpm), 5.28×105 cpm,
5.28×104 cpm, 5.28×103 cpm, 5.28×102 cpm) of pHBV 1.2 ×, which
is similar to a previously described construct (Guidotti et al., 1995).
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